[{"indications": "Indications\u00a0\n(From 8.1.3 Antimetabolites: British National Formulary)\nCapecitabine, which is metabolised to fluorouracil, is given by mouth. It is licensed as monotherapy or combination therapy for adjuvant treatment of advanced colon cancer following surgery, for monotherapy or combination therapy of metastatic colorectal cancer, and for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine is also licensed for second-line treatment of locally advanced or metastatic breast cancer either in combination with docetaxel (where previous therapy included an anthracycline) or alone (after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated). For the role of capecitabine in the treatment of breast cancer, see section 8.3.4.1. ", "name": "CAPECITABINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.3 Antimetabolites", "CAPECITABINE"], "cautions": "Cautions\u00a0see section 8.1; history of significant cardiovascular\r\ndisease, arrhythmias; monitor plasma-calcium concentration; diabetes mellitus; interactions: Appendix\r\n1 (fluorouracil) ", "side-effects": "Side-effects\u00a0see section 8.1; hand\u2013foot (desquamative) syndrome;\r\ndiarrhoea; also reported QT-prolongation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106109.htm", "doses": ["Stage III colon cancer, adjuvant following surgery,\r\nmonotherapy, adult over 18 years 1.25\u00a0g/m2 twice daily for 14 days, subsequent courses repeated after\r\na 7-day interval; recommended duration of treatment 6 months", "Stage III colon cancer, adjuvant following surgery,\r\nin combination therapy, adult over\r\n18 years 0.8\u20131\u00a0g/m2 twice daily for 14 days, subsequent\r\ncourses repeated after a 7\u2013day interval; recommended duration of treatment\r\n6 months", "Metastatic colorectal cancer, monotherapy, adult over 18 years 1.25\u00a0g/m2 twice daily\r\nfor 14 days, subsequent courses repeated after a 7-day interval", "Metastatic colorectal cancer, in combination therapy, adult over 18 years 0.8\u20131\u00a0g/m2 twice daily\r\nfor 14 days, subsequent courses repeated after a 7-day interval", "Advanced gastric cancer, in combination with a platinum-based\r\nregimen, adult over 18 years 0.8\u20131\u00a0g/m2 twice daily for 14 days, subsequent courses repeated after\r\na 7-day interval or 625\u00a0mg/m2 twice daily given continuously", "Locally advanced or metastatic breast cancer, monotherapy\r\nor in combination with docetaxel, adult over 18 years 1.25\u00a0g/m2 twice daily for 14 days, subsequent\r\ncourses repeated after a 7-day interval", "Adjust dose according to tolerability\u2014consult\r\nproduct literature"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic in animal studies);\r\nsee also Pregnancy and Reproductive\r\nFunction"}]